Sarepta Therapeutics (SRPT) Shares Soar 12.88% After Hitting 7-Year Low

Sarepta Therapeutics (SRPT) shares surged by 12.88% today, marking a significant rebound after hitting its lowest level since October 2017, with an intraday decline of 2.62%.

Sarepta Therapeutics has faced a series of challenges that have impacted its stock price. In March 2025, a 16-year-old U.S. patient died of acute liver failure after receiving Sarepta's gene therapy. This tragic incident has raised concerns about the safety and efficacy of the company's treatments, contributing to a decline in investor confidence.

Adding to the negative sentiment, Deutsche Bank Aktiengesellschaft recently lowered their price target for SRPT shares. This downgrade reflects a pessimistic outlook on the company's future performance, further weighing on the stock price.

Moreover, Sarepta announced a fatality in its Elevidys program, which has caused shares to fall by approximately 26%. This program-related concern has added to the overall negative sentiment surrounding the company, making investors cautious about its prospects.

These incidents collectively highlight the significant challenges and negative sentiment surrounding Sarepta Therapeutics, contributing to its recent stock price decline. The company will need to address these issues and regain investor trust to stabilize its stock performance.